You are here: Industry Insights > BARDA

News List

BARDA Funds Development of Tangen Biosciences’ Multi-Target Platform contractpharma
May 07, 2020
Also awards Tangen a new contract for Point-of-Care COVID-19 molecular test.
BARDA to give Moderna up to $483 million for COVID-19 vaccine development europeanpharmaceuticalreview
April 22, 2020
The US Biomedical Advanced Research and Development Authority (BARDA) will fund Moderna’s COVID-19 vaccine candidate mRNA-1273 through Phase II and III clinical trials to FDA licensure.
US BARDA commits up to $483m for Moderna Covid-19 vaccine pharmaceutical-technology
April 20, 2020
The US Biomedical Advanced Research and Development Authority (BARDA) has committed up to $483m to support the development of the Moderna mRNA vaccine candidate, mRNA-1273, against Covid-19.
BARDA funds OraSure's home spit test for coronavirus infections fiercebiotech
April 13, 2020
The U.S. federal government’s Biomedical Advanced Research and Development Authority, known as BARDA, has funded the development of a rapid coronavirus test that can be self-administered at home.
Emergent Signs $14.5M COVID-19 BARDA Deal contractpharma
April 10, 2020
Partners with U.S. government for comprehensive response to expedite development of plasma-derived therapy for COVID-19.
OraSure Gets Govt. Support to Develop In-home Coronavirus Test contractpharma
April 08, 2020
Receives BARDA contract for rapid oral fluid pan-SARS-coronavirus in-home self-test.
Paratek Gets BARDA Funding for NUZYRA Supply contractpharma
April 03, 2020
To support the development and manufacturing activities of NUZYRA for the treatment of pulmonary anthrax.
J&J partners with BARDA to commit $1bn to Covid-19 vaccine development pharmaceutical-technology
March 31, 2020
Johnson & Johnson (J&J) has expanded its partnership with the US Department for Health and Human Service (HSS)’s Biomedical Advanced Research and Development Authority (BARDA).
Mesa Biotech to Receive Funding from US Health and Human Services for Development of a 30 minute Molecular (PCR) Point-of-Care SARS-CoV-2 Test prnewswire
March 20, 2020
Mesa Biotech Inc., a privately-held, molecular diagnostic company has developed an affordable, 30 minute sample-to-answer molecular testing platform designed for point-of-care (POC) infectious disease diagnosis.
Atox Bio Announces Exercise by BARDA of Next Option Period for NSTI Treatment americanpharmaceuticalreview
June 20, 2019
Atox Bio announced the Biomedical Advanced Research and Development Authority (BARDA) has exercised the next option on a performance-based contract with for the development of Reltecimod in patients with Necrotizing Soft Tissue Infections (NSTI).

Previous page 1 2 3 4 5 Next page